Dermapharm Holding SE
XETRA:DMP

Watchlist Manager
Dermapharm Holding SE Logo
Dermapharm Holding SE
XETRA:DMP
Watchlist
Price: 37.8 EUR -0.53% Market Closed
Market Cap: 2B EUR
Have any thoughts about
Dermapharm Holding SE?
Write Note

Dermapharm Holding SE
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Dermapharm Holding SE
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Dermapharm Holding SE
XETRA:DMP
Cash from Investing Activities
-€20.8m
CAGR 3-Years
42%
CAGR 5-Years
44%
CAGR 10-Years
N/A
ATAI Life Sciences NV
NASDAQ:ATAI
Cash from Investing Activities
-$53.3m
CAGR 3-Years
-24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bayer AG
XETRA:BAYN
Cash from Investing Activities
-€2.4B
CAGR 3-Years
N/A
CAGR 5-Years
-14%
CAGR 10-Years
10%
Merck KGaA
XETRA:MRK
Cash from Investing Activities
-€2.9B
CAGR 3-Years
-29%
CAGR 5-Years
N/A
CAGR 10-Years
-14%
MPH Health Care AG
XETRA:93M1
Cash from Investing Activities
€5.4m
CAGR 3-Years
-25%
CAGR 5-Years
8%
CAGR 10-Years
N/A
PharmaSGP Holding SE
XETRA:PSG
Cash from Investing Activities
-€866k
CAGR 3-Years
1%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
No Stocks Found

Dermapharm Holding SE
Glance View

Market Cap
2B EUR
Industry
Pharmaceuticals

In the bustling world of pharmaceuticals, Dermapharm Holding SE stands as a noteworthy player, crafting a narrative of strategic growth and innovation. Founded in 1991 and headquartered in Grünwald, Germany, Dermapharm presents itself as a vertically integrated pharmaceutical company whose operations stretch from development and production to marketing and distribution. This integration allows them to maintain control over their value chain, ensuring efficiency and quality across diverse product lines. Dermapharm's portfolio spans over 900 active pharmaceutical ingredients, health products, and medical devices, fortified through keenly orchestrated acquisitions that enhance their market presence and product offerings. Such strategic steps enable Dermapharm to leverage established brands while venturing into new sectors, reinforcing its reputation as a dynamic force in the pharmaceutical landscape. Dermapharm primarily generates revenue by capitalizing on dermatological products, allergy treatments, systemic corticosteroids, and vitamin supplements. By addressing a broad spectrum of chronic and everyday health conditions, they serve both niche and mass-market demands across Europe. Dermapharm’s distinctive approach combines robust in-house research and development with targeted acquisitions, such as their acquisition of the Dr. Loges-Schuten pharmaceutical company, broadening their reach into phyto-pharmaceuticals and other sectors. Additionally, Dermapharm collaborates with partners to penetrate new geographical markets, thereby diversifying their revenue streams. Such initiatives underscore the company's agility and strategic foresight, ensuring sustained growth in a competitive industry.

DMP Intrinsic Value
43.76 EUR
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Dermapharm Holding SE's Cash from Investing Activities?
Cash from Investing Activities
-20.8m EUR

Based on the financial report for Sep 30, 2024, Dermapharm Holding SE's Cash from Investing Activities amounts to -20.8m EUR.

What is Dermapharm Holding SE's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
44%

Over the last year, the Cash from Investing Activities growth was 95%. The average annual Cash from Investing Activities growth rates for Dermapharm Holding SE have been 42% over the past three years , 44% over the past five years .

Back to Top